477 related articles for article (PubMed ID: 27058852)
21. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.
Hradska K; Kascak M; Hajek R; Jelinek T
Expert Rev Hematol; 2020 Apr; 13(4):375-392. PubMed ID: 32116068
[No Abstract] [Full Text] [Related]
22. Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.
Dada R
Ann Hematol; 2018 Apr; 97(4):555-561. PubMed ID: 29322203
[TBL] [Abstract][Full Text] [Related]
23. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
24. PD-1 checkpoint inhibition: Toxicities and management.
Hahn AW; Gill DM; Agarwal N; Maughan BL
Urol Oncol; 2017 Dec; 35(12):701-707. PubMed ID: 28889921
[TBL] [Abstract][Full Text] [Related]
25. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
Cheah CY; Fowler NH; Neelapu SS
Curr Opin Oncol; 2015 Sep; 27(5):384-91. PubMed ID: 26248256
[TBL] [Abstract][Full Text] [Related]
26. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
27. Nivolumab: targeting PD-1 to bolster antitumor immunity.
Brahmer JR; Hammers H; Lipson EJ
Future Oncol; 2015; 11(9):1307-26. PubMed ID: 25798726
[TBL] [Abstract][Full Text] [Related]
28. Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects.
Long L; Zhao C; Ozarina M; Zhao X; Yang J; Chen H
Clin Drug Investig; 2019 Apr; 39(4):341-353. PubMed ID: 30778885
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy in Lung Cancer.
Du L; Herbst RS; Morgensztern D
Hematol Oncol Clin North Am; 2017 Feb; 31(1):131-141. PubMed ID: 27912829
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint blockade in lung cancer.
Somasundaram A; Socinski MA; Villaruz LC
Discov Med; 2016 Aug; 22(119):55-65. PubMed ID: 27585231
[TBL] [Abstract][Full Text] [Related]
31. [Renaissance of immuno-oncology for urological tumors : Current status].
Grimm MO; Winkler Y; Fetter I; Oppel-Heuchel H
Urologe A; 2016 May; 55(5):621-6. PubMed ID: 27119960
[TBL] [Abstract][Full Text] [Related]
32. New checkpoint inhibitors ride the immunotherapy tsunami.
Mullard A
Nat Rev Drug Discov; 2013 Jul; 12(7):489-92. PubMed ID: 23812256
[No Abstract] [Full Text] [Related]
33. Prospects for targeting PD-1 and PD-L1 in various tumor types.
Kim JW; Eder JP
Oncology (Williston Park); 2014 Nov; 28 Suppl 3():15-28. PubMed ID: 25387682
[TBL] [Abstract][Full Text] [Related]
34. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
Pennell NA
Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472
[TBL] [Abstract][Full Text] [Related]
35. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
36. [Immunotherapy in lung cancer: checkpoint inhibitors].
Wehler T; Wehler B; Stehle I
Dtsch Med Wochenschr; 2015 Dec; 140(24):1835-8. PubMed ID: 26625234
[TBL] [Abstract][Full Text] [Related]
37. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
Dang TO; Ogunniyi A; Barbee MS; Drilon A
Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
[TBL] [Abstract][Full Text] [Related]
38. [Not Available].
Bounaix L; Bendouda M; Bay JO; Lemal R
Bull Cancer; 2016 Nov; 103 Suppl 1():S160-S163. PubMed ID: 28057180
[TBL] [Abstract][Full Text] [Related]
39. [Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma].
Adam J; Tomasic G; Robert C
Ann Pathol; 2017 Feb; 37(1):55-60. PubMed ID: 28111041
[TBL] [Abstract][Full Text] [Related]
40. Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.
Califano R; Kerr K; Morgan RD; Lo Russo G; Garassino M; Morgillo F; Rossi A
Curr Oncol Rep; 2016 Sep; 18(9):59. PubMed ID: 27484062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
